Trial Profile
Phase I/II trial of nab-Paclitaxel, Carboplatin, plus Bevacizumab chemotherapy for patients with advanced Non-Squamous Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Apr 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Mar 2021 Status changed from recruiting to completed.
- 03 Mar 2014 New trial record